AI-Supported Home Exercise Program to Relieve Joint Pain from Aromatase Inhibitors in Breast Cancer Survivors

What this Trial Is About

Researchers are evaluating an artificial intelligence AI-based skeletal recognition system designed to support real-time, interactive rehabilitation exercise programs for breast cancer survivors experiencing musculoskeletal symptoms related to endocrine therapy. This trial focuses on symptoms caused by aromatase inhibitors, such as joint pain, stiffness, and muscle weakness, which can significantly impact quality of life. The study aims to develop a home-based AI-assisted rehabilitation program tailored to improve exercise adherence and alleviate these symptoms. Participants in the intervention group will follow a home-based exercise program alongside standard rehabilitation guidance, including education on endocrine therapy-related bone and joint symptoms, psychological support, and health education. The exercise program includes aerobic warm-up routines and functional training 3 to 5 times per week, with sessions lasting 15 to 30 minutes at a moderate intensity level. The control group will receive no additional intervention beyond standard care. During the 12-week treatment period, researchers will assess outcomes such as grip strength, joint function using M-SACRAH and WOMAC scales, and range of motion. Secondary measures include symptom severity, inflammation markers, vitamin D levels, bone mineral density, and genetic markers at baseline and after 3 months. Participants will be monitored for changes in musculoskeletal symptoms and overall physical function to evaluate the programs impact.

AI-based Skeleton Recognition System for Rehabilitation Exercise in Breast Cancer Survivors: A Randomized Controlled Trial